Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502656 | 0.92 | CYP4F2 (0.33) | DGAT1CYP4F2CYP4A11 | |
| SCHEMBL6505133 | 0.85 | CYP4F2 (0.36) | DGAT1CYP4F2CYP4A11 | |
| SCHEMBL6691583 | 0.85 | CYP4F2 (0.40) | DGAT1CYP4F2CYP4A11 | |
| SCHEMBL6692896 | 0.83 | CYP4F2 (0.42) | DGAT1CYP4F2CYP4A11 | |
| SCHEMBL27596155 | 0.82 | — | — | |
| SCHEMBL6533915 | 0.81 | HRH3 (0.33) | — | |
| SCHEMBL27596099 | 0.79 | ACLY (0.42) | CYP4F2CYP4A11 | |
| SCHEMBL27578128 | 0.78 | ACLY (0.45) | CYP4F2CYP4A11 | |
| SCHEMBL2022397 | 0.78 | DGAT1 (0.44) | DGAT1CYP4F2CYP4A11 | |
| SCHEMBL6532719 | 0.77 | ACLY (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122091-A1 | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-06-24 | — | — | US | claimed |
| US-6673780-B2 | SUCH AS 4-(4-(3-HYDROXY-3-METHYL-BUTANE-1-SULFINYLMETHYL)-PHENYLMETHANESULFINYL)-2 -METHYL-BUTAN1-OL FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES, DYSLIPIDEMIAS, DYSPROTEINEMIAS, AND GLUCOSE METABOLISM DISORDERS | ESPERION THERAPEUTICS, INC. | 2004-01-06 | — | — | US | claimed |
| US-20030022865-A1 | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2003-01-30 | — | — | US | claimed |
| CN-1479721-A | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol therapy and related applications | ͨ��ҽ�ƹ�˾ | 2004-03-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122091-A1 | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses | NR1H2, NR1H3, APOB | DGAT1 196/4885CYP4F2 1278/4885CYP4A11 151/4885 |
| US-20030022865-A1 | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses | NR1H2, NR1H3, APOB | DGAT1 196/4885CYP4F2 1278/4885CYP4A11 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.